# BKM120 For Triple Negative Breast Cancer

> **NCT01790932** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01790932
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01790932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01790932, "BKM120 For Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01790932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*